基本信息
views: 6
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Liver fibrosis and its end-stage sequelae of cirrhosis and liver cancer are major causes of morbidity and mortality in Australia and throughout the world and their prevalence is rising, largely due to the increasing impact of chronic liver diseases including non-alcoholic fatty liver disease (NAFLD) and biliary diseases. It is hoped better disease prevention and more effective therapies will help reduce this disease burden. However, there remains a major need to identify potentially modifiable factors which exacerbate liver injury and fibrosis and to develop therapies that can prevent or slow liver scarring. This is particularly true for NAFLD, a disease which affects up to 30% of the adult population and is now a major cause of the premature illness and death, but for which there is still no established drug therapy.
Research Interests
Papers共 388 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Alimentary pharmacology & therapeuticsno. 8 (2024): 941-952
FRONTIERS IN PHYSIOLOGY (2022): 864083-864083
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn